Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  BioMarin Pharmaceutical Inc.    BMRN   US09061G1013

 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/25/2014 08/26/2014 08/27/2014 08/28/2014 08/29/2014 Date
70.89(c) 71.55(c) 70.8(c) 69.62(c) 71.22(c) Last
1 180 011 980 514 804 928 764 744 660 854 Volume
+1.04% +0.93% -1.05% -1.67% +2.30% Change
More quotes
Company
BioMarin Pharmaceutical, Inc. develops and commercializes innovative pharmaceuticals for serious diseases and medical conditions. The company operates its business through one segment, the biopharmaceutical development and commercialization segment. Its company's product portfolio is comprised of... 
Sector
Pharmaceuticals
Calendar
09/03Presentation
Surperformance© rating of BioMarin Pharmaceutical In
Trading Rating : Investor Rating :
More about the company
Chart BIOMARIN PHARMACEUTICAL IN
Duration : Period :
BioMarin Pharmaceutical In Technical Analysis Chart | BMRN | US09061G1013 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 755 M
EBIT 2014 -136 M
Net income 2014 -179 M
Debt 2014 249 M
Yield 2014 -
Sales 2015 862 M
EBIT 2015 -139 M
Net income 2015 -169 M
Debt 2015 300 M
Yield 2015 -
PER 2014 -
PER 2015
EV / Sales 2014 14,2x
EV / Sales 2015 12,5x
Capitalization 10 478 M
More Financials
Latest news on BIOMARIN PHARMACEUTICAL IN
6d ago BIOMARIN PHARMACEUTICAL : Assigned Patent
7d ago Roche to buy U.S. biotech firm InterMune for $8.3 billion
08/19 BIOMARIN PHARMACEUTICAL : to Present at Upcoming Investor Conferences
08/13 BIOMARIN PHARMACEUTICAL : Investigators at BioMarin Pharmaceutical Discuss Findi..
08/01 BIOMARIN PHARMACEUTICAL : Entry into a Material Definitive Agreement (form 8-K)
07/30 BIOMARIN PHARMACEUTICAL : Patent Issued for Formulations for Lysosomal Enzymes
07/30DJBioMarin Sells Priority Review Voucher To Regeneron
07/30 BIOMARIN PHARMACEUTICAL : Results of Operations and Financial Condition, Financi..
07/30 BioMarin Announces Second Quarter 2014 Financial Results
07/30 BIOMARIN PHARMACEUTICAL : Sells Priority Review Voucher for $67.5 Million
07/29 BIOMARIN PHARMACEUTICAL : Assigned Patent
07/23 BIOMARIN PHARMACEUTICAL : Sarah Cannon Research UK and BioMarin Collaborate on E..
More news
Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
BioMarin Pharmaceutical In : Income Statement Evolution
More Financials
EPS Revisions
BioMarin Pharmaceutical In : EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF